Global leadership Sandoz is a global leader in generic and biosimilar medicines with a broad portfolio of ~1,300 products and a revenue base around USD 10B, indicating a strong market position and high potential for partnership in procurement, licensing, and co-development opportunities.

Scale and reach With 10,001+ employees across 100 nationalities and annual treatments reaching 900 million patients, there is extensive distribution capacity and a mature global supply chain ripe for expansion of product lines, contract manufacturing, and regional market entry collaborations.

Cost savings leverage As a driver of substantial global healthcare savings, Sandoz presents opportunities to position new generics or biosimilars as cost-effective alternatives for payer-focused, hospital, and pharmacy channels seeking price competitiveness and volume-based contracts.

Tech-enabled partnerships The disclosed tech stack and digital tooling across SAP Hybris, GitLab, MicroStrategy, and other platforms suggest readiness for sales and supply chain integrations, data-driven pricing strategies, and joint go-to-market initiatives powered by analytics.

Historical innovation Sandoz’ heritage of breakthroughs including the world’s first biosimilar and long-standing industry leadership implies openness to collaboration on innovative development, regulatory strategy, and access programs that can accelerate market adoption for new therapies.